1478 related articles for article (PubMed ID: 8593106)
1. p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis.
Lee CS; Pirdas A; Lee MW
Australas J Dermatol; 1995 Nov; 36(4):192-5. PubMed ID: 8593106
[TBL] [Abstract][Full Text] [Related]
2. p53 immunoreactivity in human malignant melanoma and dysplastic naevi.
McGregor JM; Yu CC; Dublin EA; Barnes DM; Levison DA; MacDonald DM
Br J Dermatol; 1993 Jun; 128(6):606-11. PubMed ID: 8338744
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications.
Weiss J; Heine M; Körner B; Pilch H; Jung EG
Br J Dermatol; 1995 Jul; 133(1):23-31. PubMed ID: 7669636
[TBL] [Abstract][Full Text] [Related]
4. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type.
Akslen LA; Monstad SE; Larsen B; Straume O; Ogreid D
Int J Cancer; 1998 Feb; 79(1):91-5. PubMed ID: 9495365
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutation and expression in naevi and melanomas.
Sparrow LE; Soong R; Dawkins HJ; Iacopetta BJ; Heenan PJ
Melanoma Res; 1995 Apr; 5(2):93-100. PubMed ID: 7620345
[TBL] [Abstract][Full Text] [Related]
6. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
7. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
8. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
9. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical demonstration of the nm23-H1 gene product in human malignant melanoma and Spitz nevi.
Lee CS; Pirdas A; Lee MW
Pathology; 1996 Aug; 28(3):220-4. PubMed ID: 8912348
[TBL] [Abstract][Full Text] [Related]
11. p53 Protein expression in nevi and melanomas.
Cristofolini M; Boi S; Girlando S; Zumiani G; Cristofolini P; Dalla Palma P; Doglioni C; Barbareschi M
Arch Dermatol; 1993 Jun; 129(6):739-43. PubMed ID: 8507076
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma.
Platz A; Ringborg U; Grafström E; Höög A; Lagerlöf B
Melanoma Res; 1995 Apr; 5(2):101-6. PubMed ID: 7620336
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
[TBL] [Abstract][Full Text] [Related]
14. p53 protein expression and TP53 mutations in malignant melanomas of sun-sheltered mucosal membranes versus chronically sun-exposed skin.
Ragnarsson-Olding B; Platz A; Olding L; Ringborg U
Melanoma Res; 2004 Oct; 14(5):395-401. PubMed ID: 15457096
[TBL] [Abstract][Full Text] [Related]
15. [Expression of P53 protein in cutaneous melanoma].
Casazza S; Gambini C; Tunesi G; Rovida S; Caruso F; Pastorino A; Canepa M
Pathologica; 1993; 85(1097):335-42. PubMed ID: 8233650
[TBL] [Abstract][Full Text] [Related]
16. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin.
Vogt T; Zipperer KH; Vogt A; Hölzel D; Landthaler M; Stolz W
Histopathology; 1997 Jan; 30(1):57-63. PubMed ID: 9023558
[TBL] [Abstract][Full Text] [Related]
17. Mutation and expression of TP53 in malignant melanomas.
Weiss J; Heine M; Arden KC; Körner B; Pilch H; Herbst RA; Jung EG
Recent Results Cancer Res; 1995; 139():137-54. PubMed ID: 7597286
[TBL] [Abstract][Full Text] [Related]
18. p53 expression is rare in cutaneous melanomas.
Saenz-Santamaría MC; McNutt NS; Bogdany JK; Shea CR
Am J Dermatopathol; 1995 Aug; 17(4):344-9. PubMed ID: 8600797
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53 over-expression in thin melanomas.
Sparrow LE; English DR; Heenan PJ; Dawkins HJ; Taran J
Melanoma Res; 1995 Dec; 5(6):387-92. PubMed ID: 8589612
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
